Study of the use of aspirin to prevent colorectal cancer.
Colorectal cancer is the third leading cause of death from cancer in the United States, and advanced colorectal tumors are a major risk factor. The United States Preventive Action Task Force (USPSTF) concluded that aspirin reduces the risk of colorectal cancer by 40%, as well as recurrent cases of advanced benign tumors. The guidelines indicate that without specific contraindications, health care providers should routinely prescribe aspirin for all patients with advanced colorectal polyps.
To explore whether patients adhere to these recommendations and USPSTF vexgen keto guidelines, researchers at the Schmidt School of Medicine at Florida Atlantic University analyzed data from structured interviews of 84 patients between the ages of 40 and 91 with the removal of a tumor. of colorectal cancer on a July 1, 2013 June 30, 2017.
Data published in the American Journal of Medicine showed that only 36 (42.9 percent) of 84 patients with advanced polypologous colon and rectum reported taking aspirin.
“These data indicate a lack of aspirin use to prevent colorectal cancer and frequent benign tumors in these high-risk patients,” said Charles Henkins, MD, MD, lead author, first professor of Richard Dole, principal academic advisor at Schmidt College of Medicine in FAU.
Among the co-authors are the first author, Benjamin Fiedler, a senior scientist at Cornell University who was accepted as a freshman at the Schmidt College of Medicine; Lawrence Fiedler, MD, gastroenterologist and associate associate professor. Michael Ddonot, Ph.D., assistant professor; Kusi Anago, MD, former internal resident; Leonie de la Cruz, former medical student. George R. Luck, assistant professor, all in the Schmidt School of Medicine.